SAN DIEGO, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Nos. 8,466,183 and 8,481,573 which cover compounds including the Company's proprietary selective sphingosine-1-phosphate 1 receptor (S1P1R) modulator, RPC1063. These composition of matter patents will have an initial patent term extending to May 2029.
Receptos is pursuing broad patent coverage for its S1P1R modulator portfolio, including for compositions of matter, multiple chemical scaffolds as well as certain of their metabolites, synthetic intermediates, manufacturing methods, and methods of use. In addition to the issued US patents, multiple additional patent applications are undergoing prosecution that are anticipated to provide a strong intellectual property estate around RPC1063.
Faheem Hasnain, President and Chief Executive Officer of the Company, said, "We are pleased that the USPTO has issued these key composition of matter patents, which confirm our proprietary position in the United States for our lead product candidate RPC1063 until 2029, with the potential for Hatch-Waxman extension. Robust patent protection for RPC1063 provides the foundation for investment in multiple indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD), for which we have ongoing Phase 2 trials reading out in 2014."
About RPC1063 and S1P1R Modulators
RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator in development for autoimmune indications. Previously reported Phase 1 results demonstrated adequate pharmacokinetic, pharmacodynamic and safety features, which provide supportive data for the differentiation strategy for RPC1063 as a potential best-in-class second generation S1P1R modulator. Receptos is currently enrolling patients into the randomized Phase 2 portion of a Phase 2/3 study called RADIANCE examining the efficacy, safety and tolerability of RPC1063 in RMS and a randomized Phase 2 study called TOUCHSTONE examining the efficacy, safety and tolerability of RPC1063 in ulcerative colitis (UC). Top-line results for both studies are expected in mid-2014.
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is an S1P1R small molecule modulator candidate for immune indications, including RMS and IBD. The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated Orphan Disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).
Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as RPC1063 as well as statements regarding the scope and strength of intellectual property protection, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those
anticipated. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in the Company's SEC filings, including the Company's Quarterly Reports on Form 10-Q and the Company's Registration Statement on Form S-1 which was declared effective on May 8, 2013. All forward-looking statements contained in this release speak only as of the date on which they were first
made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.
CONTACT: Media and Investor Contacts:
Graham K. Cooper
Chief Financial Officer, Receptos
Source: Receptos, Inc.
News Provided by Acquire Media